PROCEPT BioRobotics (NASDAQ:PRCT) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

PROCEPT BioRobotics (NASDAQ:PRCT) announced its earnings results on Tuesday. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.01), FiscalAI reports. PROCEPT BioRobotics had a negative return on equity of 27.70% and a negative net margin of 31.82%.The company had revenue of $94.50 million for the quarter, compared to analyst estimates of $92.77 million. During the same quarter last year, the business posted ($0.35) earnings per share. The business’s quarterly revenue was up 19.3% on a year-over-year basis.

Here are the key takeaways from PROCEPT BioRobotics’ conference call:

• Q2 revenue rose 19% year over year to $94.5 million, supported by 65 HYDROS system placements, stronger pricing, and 32% growth in U.S. system revenue. Management maintained its full-year revenue guidance of $390 million to $410 million.
• U.S. procedures increased 21% to more than 13,100 but came in below expectations, primarily because of softness in legacy AquaBeam accounts. Full-year procedure guidance was reduced to 54,000–56,000, with the low end assuming no improvement in AquaBeam utilization.
• HYDROS accounts are generating significantly more procedures per account than legacy AquaBeam sites, while launch-team-supported accounts are showing faster time to first case and stronger early utilization. PROCEPT is accelerating replacements, completing 14 in Q2 and now expecting approximately 40 for the full year.
• Operating expenses increased to $89.8 million, driving a $26.9 million net loss and an $11.3 million adjusted EBITDA loss in Q2. The company raised full-year operating expense guidance to $355 million–$360 million, although it still expects positive adjusted EBITDA in Q4.
• The American Urological Association strengthened its recommendation for Aquablation, and PROCEPT completed enrollment of all 280 patients in the WATER IV randomized prostate cancer trial. The company also received FDA IDE approval for a second randomized trial comparing Aquablation with active surveillance.

PROCEPT BioRobotics Stock Down 0.5%

Shares of NASDAQ PRCT traded down $0.10 during trading hours on Tuesday, hitting $18.28. The company had a trading volume of 3,692,057 shares, compared to its average volume of 1,568,284. The stock has a market capitalization of $1.04 billion, a P/E ratio of -10.04 and a beta of 0.89. The company has a quick ratio of 5.51, a current ratio of 6.73 and a debt-to-equity ratio of 0.15. PROCEPT BioRobotics has a 1-year low of $16.67 and a 1-year high of $49.90. The firm’s 50 day moving average is $21.99 and its 200-day moving average is $24.97.

Hedge Funds Weigh In On PROCEPT BioRobotics

A number of institutional investors have recently added to or reduced their stakes in the company. Prosight Management LP lifted its stake in shares of PROCEPT BioRobotics by 1,692.4% during the 4th quarter. Prosight Management LP now owns 1,380,000 shares of the company’s stock worth $43,415,000 after buying an additional 1,303,009 shares during the last quarter. Alliancebernstein L.P. grew its position in shares of PROCEPT BioRobotics by 58.6% in the third quarter. Alliancebernstein L.P. now owns 3,419,784 shares of the company’s stock valued at $122,052,000 after purchasing an additional 1,262,928 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its stake in shares of PROCEPT BioRobotics by 59.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,271,408 shares of the company’s stock worth $102,919,000 after purchasing an additional 1,218,815 shares during the period. UBS Group AG increased its stake in shares of PROCEPT BioRobotics by 129.3% during the third quarter. UBS Group AG now owns 944,545 shares of the company’s stock worth $33,711,000 after purchasing an additional 532,530 shares during the period. Finally, Millennium Management LLC lifted its holdings in PROCEPT BioRobotics by 690.0% during the 4th quarter. Millennium Management LLC now owns 383,137 shares of the company’s stock worth $12,053,000 after purchasing an additional 448,077 shares during the last quarter. 89.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts recently issued reports on PRCT shares. Citigroup downgraded PROCEPT BioRobotics to a “hold” rating in a report on Thursday, July 2nd. Wall Street Zen raised PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. UBS Group cut shares of PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 target price for the company. in a report on Tuesday, July 28th. Truist Financial reaffirmed a “hold” rating and issued a $25.00 target price (down from $30.00) on shares of PROCEPT BioRobotics in a research report on Thursday, July 2nd. Finally, Piper Sandler reiterated an “overweight” rating and issued a $35.00 price target (up from $28.00) on shares of PROCEPT BioRobotics in a research note on Thursday, April 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, eight have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $33.45.

Key Headlines Impacting PROCEPT BioRobotics

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Positive Sentiment: Second-quarter revenue rose 19.3% year over year to $94.5 million, exceeding analysts’ $92.77 million estimate. The results were supported by continued growth in the company’s urology surgical-robotics business. PROCEPT BioRobotics Reports Second Quarter 2026 Financial Results

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.